About Cabaletta Bio
Cabaletta Bio (NASDAQ: CABA) is focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases. Our Cabaletta Approach to B cell Ablation (CABA™) platform – encompassing Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) as well as Cabaletta’s proprietary Chimeric AutoAntibody Receptor T (CAART) cells – has potential applicability across more than two dozen B cell-mediated autoimmune diseases, including indications such as systemic lupus erythematosus (SLE), rheumatoid arthritis, myositis and systemic sclerosis. Our technology is based on the revolutionary Chimeric Antigen Receptor (CAR) T cell technology developed at the University of Pennsylvania that resulted in one of the first commercially-available CAR T cell products for the treatment of B cell malignancies. Cabaletta has an exclusive global licensing agreement and multiple sponsored research agreements with the University of Pennsylvania to develop engineered T cell therapies to treat B cell-mediated autoimmune diseases.
Cabaletta’s lead CAART product candidate, DSG3-CAART, is currently under clinical investigation in the DesCAARTes™ trial in patients with mucosal pemphigus vulgaris (mPV), which is a rare autoimmune blistering disorder that causes painful blisters and sores on mucous membranes leading to severe and sometimes debilitating and life-altering effects. Cabaletta is also pursuing additional pipeline candidates for other B cell mediated disorders including MuSK Myasthenia Gravis (MG), mucocutaneous PV and PLA2R positive membranous nephropathy (MN).